Collaboration between pharmaceutical companies and healthcare professionals is essential to deliver innovative drugs to patients. However, at the same time, strict conflict of interest management is necessary. As an industry that affects lives, we believe that transparency of corporate activities is particularly critical.

Initiatives with Medical Institutions and Patient Groups

In Japan, we disclose information on payments to medical institutions and patient groups on our website in accordance with our basic policy on transparency in relationships with medical institutions and patient groups. In the United States, in accordance with the Sunshine Act, and in Europe with EFPIA (European Federation of Pharmaceutical Industries and Associations) Code, information on payments to medical institutions and other parties is disclosed on a calendar-year basis. Transparency is also required in other countries, and the entire Group is working to ensure transparency in its relationships with medical institutions and patient groups.

Research Support Initiatives

In terms of clinical research support, the Company has implemented the Daiichi Sankyo Researcher-initiated Clinical Research Recruiting Program, for which researchers can apply directly through our website. The program establishing a system to support research complies with the Clinical Trials Act.
At the same time, the Company is further enhancing compliance education for MSLs^*who support clinical research activities and promoting activities in compliance with the guidelines and related laws and regulations while continuing to prepare and monitor records in accordance with the “Guidelines for Provision of Sales Information on Prescription Drugs.” In Japan, we have introduced a Daiichi Sankyo Scholarship Donation Program for the purpose of contributing to the development of life sciences, including medicine and pharmacology, to which universities and other research institutions can apply directly through our website.

*MSL: Medical Science Liaison